Cancer Family
Reproductive System Neoplasm
CI-CAN-00000338Explore in graph →
Non-malignant3,048 active trials38 approved drugs197 evidence items
- NCIt
- C3674
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000338Explore in graph →
Clinical trials
13,679 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04231981 | Efficacy of INCMGA00012 in Penile Squamous Cell Carcinoma (ORPHEUS)(ORPHEUS) | completed | Phase 2 | 18 | MedSIROTHER | 2 | May 29, 2025 | clinicaltrials |
| NCT06312670 | Combining EPI-7386 With Enzalutamide and Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer | completed | Phase 2 | 13 | Pedro Barata, MD, MScOTHER | 1 | May 29, 2025 | clinicaltrials |
| NCT03108131 | Cobimetinib and Atezolizumab in Treating Participants With Advanced or Refractory Rare Tumors | completed | Phase 2 | 49 | M.D. Anderson Cancer CenterOTHER | 1 | May 28, 2025 | clinicaltrials |
| NCT04574284 | A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule in Subjects With Advanced Endometrial Cancer | completed | Phase 2 | 170 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | May 28, 2025 | clinicaltrials |
| NCT02713386 | Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 1 / Phase 2 | 147 | NRG OncologyOTHER | 1 | May 25, 2025 | clinicaltrials |
| NCT04513665 | ZW25 in Women With Endometrial Cancers | completed | Phase 2 | 16 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 22, 2025 | clinicaltrials |
| NCT06389695 | Pharmacokinetics, Biodistribution, Radiation Dose and Safety Study of 68Ga-NYM032 in Patients | completed | Phase 1 / Phase 2 | 20 | Norroy Bioscience Co., LTDINDUSTRY | 1 | May 21, 2025 | clinicaltrials |
| NCT04390880 | 18F-DCFPyL PET/CT Impact on Treatment Strategies for Patients With Prostate Cancer(PROSPYL) | completed | Phase 2 | 239 | VA Greater Los Angeles Healthcare SystemFED | 1 | May 16, 2025 | clinicaltrials |
| NCT02788773 | Durvalumab With or Without Tremelimumab in Metastatic Castration Resistant Prostate Cancer | completed | Phase 2 | 52 | Canadian Cancer Trials GroupNETWORK | 1 | May 15, 2025 | clinicaltrials |
| NCT02278185 | Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer | completed | Phase 2 | 19 | University of Colorado, DenverOTHER | 1 | May 11, 2025 | clinicaltrials |
| NCT04332744 | Enzalutamide Plus Talazoparib for the Treatment of Hormone Sensitive Prostate Cancer (ZZ-First)(ZZ-First) | completed | Phase 2 | 54 | MedSIROTHER | 1 | May 11, 2025 | clinicaltrials |
| NCT03570619 | Immunotherapy in Patients With Metastatic Cancers and CDK12 Mutations(IMPACT) | completed | Phase 2 | 56 | University of Michigan Rogel Cancer CenterOTHER | 1 | May 8, 2025 | clinicaltrials |
| NCT01162135 | Digoxin for Recurrent Prostate Cancer | completed | Phase 2 | 16 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | May 4, 2025 | clinicaltrials |
| NCT01848067 | Alisertib, Abiraterone Acetate and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer | completed | Phase 1 / Phase 2 | 9 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | May 4, 2025 | clinicaltrials |
| NCT02632448 | A Study of LY2880070 in Participants With Advanced or Metastatic Cancer | completed | Phase 1 / Phase 2 | 229 | Esperas Pharma Inc.OTHER | 4 | May 2, 2025 | clinicaltrials |
| NCT02967458 | Detection of High Grade Prostate Cancer With Subharmonic Ultrasound Imaging, A Pilot Study | completed | Phase 2 | 55 | Thomas Jefferson UniversityOTHER | 1 | Apr 30, 2025 | clinicaltrials |
| NCT03822845 | Evaluating the Clinical Accuracy of Gallium-68 PSMA PET/CT Imaging in Patients With Biochemical Recurrence of Prostate Cancer | completed | Phase 2 / Phase 3 | 6 | Michael Graham PhD, MDOTHER | 1 | Apr 17, 2025 | clinicaltrials |
| NCT02025010 | Study of Abiraterone Acetate Without Exogenous Glucocorticoids in Men With Castration-resistant Prostate Cancer | completed | Phase 2 | 60 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 15, 2025 | clinicaltrials |
| NCT02487095 | Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Small Cell Cancers | completed | Phase 1 / Phase 2 | 62 | National Cancer Institute (NCI)NIH | 1 | Apr 13, 2025 | clinicaltrials |
| NCT03654638 | Soy Bread Diet in Improving Immune Function in Participants With Prostate Cancer | completed | Phase 2 | 25 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Apr 4, 2025 | clinicaltrials |
| NCT04600336 | Testing the Effects of Oxybutynin for the Treatment of Hot Flashes in Men Receiving Hormone Therapy for Prostate Cancer | completed | Phase 2 | 88 | Alliance for Clinical Trials in OncologyOTHER | 1 | Mar 30, 2025 | clinicaltrials |
| NCT00513786 | Evaluation of Carboplatin/Paclitaxel/Bevacizumab in the Treatment of Advanced Stage Endometrial Carcinoma | completed | Phase 2 | 38 | David O'MalleyOTHER | 1 | Mar 28, 2025 | clinicaltrials |
| NCT03093428 | Study Evaluating the Addition of Pembrolizumab to Radium-223 in mCRPC | completed | Phase 2 | 45 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 28, 2025 | clinicaltrials |
| NCT05137067 | A Novel Approach for Alleviating the Side Effects of Chemotherapeutic Agents. | completed | Phase 2 | 90 | Optimal Health ResearchOTHER | 1 | Mar 21, 2025 | clinicaltrials |
| NCT02649790 | Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications | completed | Phase 1 / Phase 2 | 277 | Karyopharm Therapeutics IncINDUSTRY | 5 | Mar 19, 2025 | clinicaltrials |
| NCT02684227 | Enzalutamide, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrioid Endometrial Cancer | completed | Phase 2 | 50 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 19, 2025 | clinicaltrials |
| NCT02098343 | p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246 | completed | Phase 1 / Phase 2 | 247 | Aprea TherapeuticsINDUSTRY | 8 | Mar 17, 2025 | clinicaltrials |
| NCT02489903 | RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT) | completed | Phase 2 | 139 | EpicentRx, Inc.INDUSTRY | 1 | Mar 17, 2025 | clinicaltrials |
| NCT03268382 | p53 Activation in Platinum-Resistant High Grade Serous Ovarian Cancer, a Study of PLD With APR-246 | completed | Phase 2 | 36 | Aprea TherapeuticsINDUSTRY | 3 | Mar 17, 2025 | clinicaltrials |
| NCT04832958 | Imaging Guided Surgery to Improve the Detection of Lymph Node Metastases in Prostate Cancer Patients | completed | Phase 2 | 81 | IRCCS San RaffaeleOTHER | 1 | Mar 14, 2025 | clinicaltrials |
| NCT03206047 | Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 1 / Phase 2 | 12 | National Cancer Institute (NCI)NIH | 1 | Mar 13, 2025 | clinicaltrials |
| NCT04380805 | A Study of AK104, a PD-1/CTLA-4 Bispecific Antibody in Subjects With Recurrent/Metastatic Cervical Cancer | completed | Phase 2 | 30 | AkesoINDUSTRY | 3 | Feb 28, 2025 | clinicaltrials |
| NCT04870177 | Study of AK112 in the Treatment of Advanced Gynecological Tumors | completed | Phase 2 | 53 | AkesoINDUSTRY | 1 | Feb 28, 2025 | clinicaltrials |
| NCT01309672 | S1014 Abiraterone Acetate in Treating Patients With Prostate Cancer Who Have Undergone Initial Hormone Therapy | completed | Phase 2 | 41 | SWOG Cancer Research NetworkNETWORK | 1 | Feb 26, 2025 | clinicaltrials |
| NCT02428192 | Nivolumab Alone or in Combination With Ipilimumab in Treating Patients With Advanced Uterine Leiomyosarcoma | completed | Phase 2 | 20 | National Cancer Institute (NCI)NIH | 1 | Feb 25, 2025 | clinicaltrials |
| NCT04517357 | A Phase 2 Trial of Fluzoparib Combined With Apatinib Versus Fluzoparib Monotherapy in Treatment With Relapsed Ovarian Cancer Patients | completed | Phase 2 | 100 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Feb 24, 2025 | clinicaltrials |
| NCT04357873 | Efficacy of Immunotherapy Plus a Drug in Patients With Progressive Advanced Mucosal Cancer of Different Locations(PEVOsq) | completed | Phase 2 | 112 | UNICANCEROTHER | 1 | Feb 19, 2025 | clinicaltrials |
| NCT04951921 | Hyperpolarized 13C Pyruvate MRI for Early Immune Evaluation in Cervical Cancer Patients At Baseline and CCRT Therapy | completed | Phase 2 | 6 | Chang Gung Memorial HospitalOTHER | 1 | Feb 12, 2025 | clinicaltrials |
| NCT01652196 | Aflibercept and FOLFOX6 Treatment for Previously Untreated Stage IV Colorectal Cancer | completed | Phase 2 | 56 | John HaysOTHER | 1 | Feb 5, 2025 | clinicaltrials |
| NCT01814501 | Panitumumab and Chemotherapy in Patients With Advanced Colorectal Cancer After Prior Therapy With Bevacizumab | completed | Phase 2 | 16 | John HaysOTHER | 1 | Feb 5, 2025 | clinicaltrials |
| NCT00753545 | Assessment of Efficacy of AZD2281 in Platinum Sensitive Relapsed Serous Ovarian Cancer | completed | Phase 2 | 265 | AstraZenecaINDUSTRY | 17 | Feb 3, 2025 | clinicaltrials |
| NCT05496231 | A Study on the Immune Response and Safety of an Adjuvanted Human Papillomavirus Vaccine When Given to Healthy Women 16 to 26 Years of Age | completed | Phase 1 / Phase 2 | 1,080 | GlaxoSmithKlineINDUSTRY | 8 | Feb 3, 2025 | clinicaltrials |
| NCT01254864 | Maximal Androgen Depletion Followed by Randomization of Maximal Androgen Ablation With Molecular Targeted Therapies | completed | Phase 2 | 190 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 27, 2025 | clinicaltrials |
| NCT04869488 | A Trial of SHR3162 Combined With Apatinib Mesylate Tablets or SHR3162 Monotherapy in Patients With Metastatic Castration Resistant Prostate Cancer | completed | Phase 2 | 93 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jan 24, 2025 | clinicaltrials |
| NCT03532139 | Pilot Study of Rosuvastatin and Enoxaparin Thromboprophylaxis Following Ovarian Cancer Surgery (O-STAT Study) | completed | Phase 2 | 24 | Beth Israel Deaconess Medical CenterOTHER | 1 | Jan 23, 2025 | clinicaltrials |
| NCT04275713 | Altered Tumor Oxygenation by Metformin, a Potential Step in Overcoming Radiotherapy Resistance in LACC(METOXY-LACC) | completed | Phase 2 | 41 | Oslo University HospitalOTHER | 1 | Jan 20, 2025 | clinicaltrials |
| NCT04487847 | 18F-PSMA-1007 PET Imaging to Detect Primary Prostate Cancer(PICture) | completed | Phase 1 / Phase 2 | 75 | Radboud University Medical CenterOTHER | 1 | Jan 16, 2025 | clinicaltrials |
| NCT03518606 | Metronomic Oral Vinorelbine Plus Anti-PD-L1/Anti-CTLA4 ImmunothErapy in Patients With Advanced Solid Tumours(MOVIE) | completed | Phase 1 / Phase 2 | 126 | UNICANCEROTHER | 1 | Jan 15, 2025 | clinicaltrials |
| NCT03314740 | Best Approach in Recurrent-Ovarian-Cancer-with Cediranib-Olaparib(BAROCCO) | completed | Phase 2 | 123 | Mario Negri Institute for Pharmacological ResearchOTHER | 1 | Jan 10, 2025 | clinicaltrials |
Data updated 24 days agoSource updated May 29, 2025source: clinicaltrials